Copy of newspaper publication with respect to financial results for the quarter and year ended March 31, 2026
SOLARA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Solara Active Pharma Sciences has published its Q4 FY26 and full year FY26 financial results. On a standalone basis, total income from operations was Rs. 387.29 Crores for Q4 FY26 compared to Rs. 273.01 Crores in Q4 FY25. Net profit after tax for Q4 stood at Rs. 9.60 Crores versus a loss of Rs. 2.10 Crores in the same quarter last year. For the full year FY26, standalone total income was Rs. 1,368.98 Crores vs Rs. 1,283.76 Crores in FY25. On a consolidated basis, total income for FY26 was Rs. 911.90 Crores with net profit after tax of Rs. 152.53 Crores, a significant recovery from Rs. 29.40 Crores in FY25. During the year, the company raised Rs. 312.79 Crores via a rights issue and issued 2 bonus shares for every 1 share held in September 2025. The statutory auditors have expressed an unmodified opinion on the results.
Strong recovery in profitability year-on-year, with Q4 and full year returning to profit. The bonus issue and rights issue indicate active capital restructuring. The significant jump in consolidated net profit (from ~Rs. 29 Crores to ~Rs. 153 Crores) signals operational improvement.